A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma

Hematology

Volumn 11, Issue 1, 2006, Pages 25-29

  Kuruvilla, John ^a   Song, Kevin ^a   Mollee, Peter ^a   Panzarella, Tony ^b   McCrae, Jan ^a   Nagy, Tracy ^a   Crump, Michael ^a   Keating, Armand ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Autologous stem cell transplantation; Complete remission; Hodgkin's lymphoma; Thalidomide

Indexed keywords

THALIDOMIDE; VINBLASTINE;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD CELL COUNT; CANCER PALLIATIVE THERAPY; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DIZZINESS; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; HODGKIN DISEASE; HUMAN; MALE; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REMISSION; SOMNOLENCE; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HODGKIN DISEASE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PALLIATIVE CARE; REMISSION INDUCTION; STEM CELL TRANSPLANTATION; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VINBLASTINE;

EID: 33644832050     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1080/10245330500276592     Document Type: Article

References (37)

1. DeVita, VT, Jr and Hubbard, SM. (1993) Hodgkin's disease N Engl J Med, 328, pp. 560 - 655.
2. Yuen, AR and Rosenberg, SA and Hoppe, RT and (1997) Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease Blood, 89, pp. 814 - 822.
3. Lazarus, HM andRowlings, PA and Zhang, MJ and (1999) Autotransplants for Hodgkin's disease in patients never achieving remission: A report from the autologous blood and marrow transplant registry J Clin Oncol, 17, pp. 534 - 545.
4. Schmitz, N and Pfistner, B and Sextro, M and (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial Lancet, 359, pp. 2065 - 2271.
5. Linch, DC and Winfield, D and Goldstone, AH and (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial Lancet, 341, pp. 1051 - 1104.
6. Little, R and Wittes, RE and Longo, DL and (1998) Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant J Clin Oncol, 16, pp. 584 - 658.
7. Zinzani, PL and Bendandi, M and Stefoni, V and (2000) Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients Haematologica, 85, pp. 926 - 999.
8. Santoro, A and Bredenfeld, H and Devizzi, L and (2000) Gemcitabine in the treatment of refractory Hodgkin's disease: Results of a multicenter phase II study J Clin Oncol, 18, pp. 2615 - 3269.
9. D'Amato, RJ and Loughnan, MS and Flynn, E and (1994) Thalidomide is an inhibitor of angiogenesis Proc Natl Acad Sci USA, 91, pp. 4082 - 4405.
10. Baidas, SM and Winer, EP and Fleming, GF and (2000) Phase II evaluation of thalidomide in patients with metastatic breast cancer J Clin Oncol, 18, pp. 2710 - 3277.
11. Bertolini, F and Mingrone, W and Alietti, A and (2001) Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers Ann Oncol, 12, pp. 987 - 990.
12. Drake, MJ and Robson, W and Mehta, P and (2003) An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer Br J Cancer, 88, pp. 822 - 887.
13. Kaufmann, H and Raderer, M and Wohrer, S and (2004) Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma Blood, 104, pp. 2269 - 2271.
14. Piccaluga, PP and Visani, G and Pileri, SA and (2002) Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study Leukemia, 16, pp. 1609 - 2114.
15. Singhal, S and Mehta, J and Desikan, R and (1999) Antitumor activity of thalidomide in refractory multiple myeloma N Engl J Med, 341, pp. 1565 - 2171.
16. Cheson, BD and Horning, SJ and Coiffier, B and (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI sponsored international working group J Clin Oncol, 17, pp. 1244.
17. Ezdinli, EZ and Stutzman, L:. (1968) Vinblastine vs. nitrogen mustard therapy of Hodgkin's disease Cancer, 22, pp. 473 - 549.
18. Duggan, DB and Petroni, GR and Johnson, JL and (2003) Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial J Clin Oncol, 21, pp. 607 - 614.
19. Skinnider, BF and Mak, TW. (2002) The role of cytokines in classical Hodgkin lymphoma Blood, 99, pp. 4283 - 4497.
20. Doussis-Anagnostopoulou, IA and Talks, KL and Turley, H and (2002) Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-reed-sternberg cells in Hodgkin's disease J Pathol, 197, pp. 677 - 883.
21. Giles, FJ and Vose, JM and Do, KA and (2004) Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma Leuk Res, 28, pp. 595 - 604.
22. Folkman, J. (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst, 82, pp. 4 - 6.
23. Geitz, H and Handt, S and Zwingenberger, K. (1996) Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade Immunopharmacology, 31, pp. 213 - 221.
24. Sampaio, EP and Sarno, EN and Galilly, R and (1991) Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes J Exp Med, 173, pp. 699 - 703.
25. Haslett, PA and Corral, LG and Albert, M and (1998) Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset J Exp Med, 187, pp. 1885 - 2192.
26. McHugh, SM and Rifkin, IR and Deighton, J and (1995) The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures Clin Exp Immunol, 99, pp. 160 - 217.
27. Pro, B and Younes, A and Albitar, M and (2004) Thalidomide for patients with recurrent lymphoma Cancer, 100, pp. 1186 - 2119.
28. Younes, A and Romaguera, J and Hagemeister, F and (2003) A pilot study of rituximab in patients with recurrent, classic Hodgkin disease Cancer, 98, pp. 310 - 334.
29. Younes, A and Pro, B and Romaguera, J and (2004) Safety and efficacy of bortezomib (velcade) for the treatment of relapsed classical Hdogkin's disease Blood, 104, pp. 2638.
30. Leonard, JP and Rosenblatt, JD and Bartlett, N and (2004) Phase II study of SGN-30 (Anti-CD30 monoclonal antibody) in patients with refractory or recurrent Hodkgin's disease Blood, 104, pp. 2635.
31. Corral, LG and Kaplan, G:. (1999) Immunomodulation by thalidomide and thalidomide analogues Ann Rheum Dis, 58(Suppl. 1), pp. I107 - I113.
32. Muller, GW and Chen, R and Huang, SY and (1999) Amino-substituted thalidomide analogs: Potent inhibitors of TNF-alpha production Bioorg Med Chem Lett, 9, pp. 1625 - 2130.
33. Hideshima, T and Chauhan, D and Shima, Y and (2000) Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy Blood, 96, pp. 2943 - 3250.
34. Gupta, D and Treon, SP and Shima, Y and (2001) Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: Therapeutic applications Leukemia, 15, pp. 1950 - 2161.
35. Davies, FE and Raje, N and Hideshima, T and (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma Blood, 98, pp. 210 - 226.
36. Richardson, PG and Schlossman, RL and Weller, E and (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma Blood, 100, pp. 3063 - 3307.
37. Miller, KC and Czuczman, MS and Dimiceli, L and (2005) Antileukemic effects of novel immunomodulatory agent lenalidomide (L) with or without rituximab (R) in patients (pts) with relapsed (rel) or refractory (ref) chronic lymphocytic leukemia (CLL). Encouraging preliminary results of an ongoing phase II clinical study J Clin Oncol, 23, pp. 6557.